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The goal of this study was to evaluate the risk of developing acute myocardial infarction (AMI) following 
retinal vein occlusion (RVO). A retrospective cohort study was performed from the National Health 
Insurance Service and comprised 1,025,340 random subjects who were followed from 2002 to 2013. 
Patients with RVO in 2002 were excluded. The RVO group was composed of patients who received an 
initial RVO diagnosis between January 2003 and December 2007 (n = 1677). The comparison group 
was selected (five patients per RVO patient; n = 8367) using propensity score matching according to 
sociodemographic factors and the year of enrolment. Each patient was tracked until 2013. The Cox 
proportional hazard regression model was used. AMI developed in 7.6% of the RVO group and 5.3% 
of the comparison group (p < 0.001) for 7.7 median follow-up periods. RVO increased the risk of AMI 
development [hazard ratio (HR) = 1.25; 95% Confidence Interval (CI) 1.02 to 1.52]. In the subgroup 
analysis, RVO patients aged <65 years and the males within this age group had an adjusted HR of 1.47 
(95% CI 1.10 to 1.98) and an adjusted HR of 2.00 (95% CI 1.38 to 2.91) for AMI development, respectively. 
RVO was significantly associated with AMI development.
Retinal vein occlusion (RVO) is classified into central RVO (CRVO) and branch RVO (BRVO)1 and is an ischemic 
event that affects the retina, which is a structure derived from the central nervous system2. RVO is associated with 
thrombosis in the vein due to compression by an adjacent atherosclerotic artery, an increased homocysteine level, 
and rheological alterations, including decreased blood flow and increased blood viscosity3–6. RVO is commonly 
associated with conditions such as hypertension, diabetes mellitus, and a wide variety of haematological disor-
ders7,8. These risk factors for RVO are also risk factors for fatal systemic vascular diseases, such as cardiovascular 
or cerebrovascular disease9,10. Several studies have analysed the association between RVO and cardiovascular 
disease, but the results have been inconsistent11–17. However, recent well-designed, large-scale studies in Taiwan14 
and the United States15 did not show a significant association between RVO and the prospective risk of acute 
myocardial infarction (AMI) development.
In this study, we investigated the association between RVO and the prospective risk of AMI development 
using a nationwide representative sample of 1,025,340 adults from the National Health Insurance Service National 
Sample Cohort 2002–2013 (NHIS-NSC 2002–2013) in South Korea.
Methods
Ethical approval. This study adhered to the tenets of the Declaration of Helsinki, and the NHIS-NCS 2002–
2013 project was approved by the Institutional Review Board of the Korean National Health Insurance Service. 
This study design was reviewed and approved by the Institutional Review Board of the National Health Insurance 
Service, Ilsan Hospital, Gyeonggi-do, Korea. Written informed consent was waived.
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Data Sources. Korea has maintained a nationwide health insurance system since 1963 under the Korean 
National Health Insurance Service (KNHIS), and nearly all of the data in the health system are centralized in large 
databases. Claims are accompanied by data regarding diagnostic codes, procedures, prescription drugs, personal 
information, and medical costs. No patient health care records are duplicated or omitted because all Korean resi-
dents receive a unique identification number at birth. Furthermore, the KNHIS uses the Korean Classification of 
Diseases (KCD), which is a system similar to the International Classification of Diseases (ICD). This study used 
the NHIS-NSC 2002–2013, which comprised 1,025,340 nationally representative random subjects accounting for 
approximately 2.2% of the entire population in 2002.
Study Population. The RVO group included all patients who received inpatient and outpatient care between 
January 2003 and December 2007 for an initial diagnosis of RVO [KCD code H34.8 corresponding to ICD-
9-clinical modification (CM) code 362.35, CRVO, or 362.36, venous tributary (branch) occlusion]. We excluded 
subjects treated for RVO in ambulatory and inpatient care in 2002 to eliminate patients with a chronic condition 
and to ensure that the RVO group included only subjects with new episodes. For the same reason, patients who 
received a diagnosis of AMI in 2002 (KCD code I21 corresponding to ICD-9-CM code 410, AMI) were also 
considered to have a chronic condition and were excluded. We included patients who were diagnosed with RVO 
prior to their AMI based on the patient’s first visit. Finally, 1677 eligible patients with RVO in 2003–2007 were 
identified after excluding potential pre-existing cases of RVO and/or AMI. These patients were regarded as new 
incident RVO. We selected 8367 patients (five per RVO patient) from the database; these patients were matched to 
the RVO group using propensity score matching. Each patient was tracked on the basis of his or her ambulatory 
visit date and the first visit date for inpatient care over the 11 year period from 2003 to 2013 to identify patients 
who developed AMI.
Comorbidities. We defined hypertension (KCD code I10 corresponding to ICD-9-CM code 401, essential 
hypertension), diabetes mellitus (KCD code E10–E14 corresponding to ICD–9–CM code 250, Diabetes mel-
litus), chronic renal failure (KCD code N18 corresponding to ICD-9-CM code 585, Chronic kidney disease), 
hyperlipidaemia (KCD code E78.0–78.5 corresponding to ICD–9–CM code 272.0, pure hypercholesterolemia, 
272.1, pure hyperglyceridaemia, 272.2, mixed hyperlipidaemia, 272.3, hyperchylomicronaemia, and 272.4, other 
and unspecified hyperlipidaemia), and stroke (KCD code I60–I63 corresponding to ICD-9-CM code 430–434, 
cerebrovascular disease) as comorbidities because they were all known risk factors for AMI10,18. The comorbidities 
were defined as a diagnosis of any of these conditions between 2003 and 2013 and prior to the AMI diagnosis.
Statistical Analysis. Descriptive statistics of the study population are presented. Propensity score matching 
was performed; to predict RVO occurrence, propensity scores were estimated using logistic regression to control 
for the sociodemographic factors age (<50, 50–59, 60–69, 70–79, and ≥ 80 years), gender, residential area (the 
Korean metropolitan area Seoul, the 2nd area including the largest province, the 3rd area including the second 
largest city and the 2nd and 3rd largest provinces, and the 4th area including other areas), and household income 
(≤30%, 30–70%, and 70–100% of the median). Matching was performed using the Greedy 8 → 1 digit matching 
macro with the estimated propensity score in each year from 2003 to 200719. To identify the hazards associated 
with AMI, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated via univariable and multivar-
iable Cox proportional hazard regression analyses. The overall AMI-free survival rate was determined using the 
Kaplan-Meier curve for the 11-year follow-up period. Follow-up began at the first date of RVO diagnosis or at a 
randomly selected index date in the matched year for the comparison group. Follow-up ended at the last visit date 
up to 2013 for subjects without subsequent AMI or the first date of AMI diagnosis. A significance level of p < 0.05 
was selected. The statistical packages SAS System for Windows, version 9.4 (SAS Institute Inc., Cary, NC, USA) 
and Stata/MP version 14.0 (StataCorp, College Station, TX, USA) were used to perform the analyses in this study.
Results
Table 1 displays the characteristics of the study population for the two cohorts (the RVO group and the compar-
ison group). The subjects with RVO were more likely to experience AMI (p < 0.001), hypertension (p < 0.001), 
diabetes mellitus (p < 0.001), chronic renal failure (p < 0.001), hyperlipidaemia (p < 0.001) and stroke (p = 0.020) 
than the comparison group. No significant difference in the year of RVO diagnosis, age, gender, residential area, 
or household income was detected between the groups because these variables were used for sample matching.
Table 2 displays the HRs for AMI during the up to 11-year follow-up period calculated using univariable and 
multivariable Cox regression models. After adjusting for age, household income, and comorbidities including 
hypertension, diabetes mellitus, chronic renal failure, hyperlipidaemia, and stroke, RVO was associated with the 
prospective development of AMI (HR = 1.25, 95% CI 1.02 to 1.52) based on the multivariable Cox regression 
analysis. Hypertension (HR = 2.64, 95% CI 1.98 to 3.50), chronic renal failure (HR = 1.83, 95% CI 1.35 to 2.49), 
and stroke (HR = 1.59, 95% CI 1.02 to 2.46) were associated with the development of AMI. In terms of socio-
demographic characteristics, increasing age was significantly associated with the development of AMI and the 
female gender was associated with a lower incidence of AMI.
Table 3 shows the subgroup analysis of age stratified into two subgroups (< 65 and ≥ 65 years) based on the 
multivariable Cox regression analysis. RVO patients aged < 65 years had a significantly higher risk for the devel-
opment of AMI (HR = 1.47, 95% CI 1.10 to 1.98). However, RVO was no longer a significant predictor for AMI 
development in the ≥ 65 year age group. In both age groups (< 65 years and ≥ 65 years), hypertension and chronic 
renal failure were associated with AMI. A gender difference existed in both age groups.
Table 4 shows the gender subgroup analysis in the <65 year age group. Male RVO patients <65 years had 
a higher risk for the development of AMI (HR = 2.00, 95% CI 1.38 to 2.91). Conversely, RVO was no longer a 
significant predictor for the development of AMI in females aged < 65 years. Hypertension was associated with 
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an increased risk of AMI for both genders. Chronic renal failure was associated with an increased risk of AMI in 
males, and stroke was associated with an increased risk of AMI in females.
Figure 1 displays the Kaplan-Meier curve for the AMI-free survival rate. The median follow-up was 7.7 years. 
A total of 73,411 person-years were examined (12,188 person-years for the RVO group and 61,223 person-years 
for the matched controls). AMI occurred at a rate of 10.5 per 1000 person-years in the RVO group and 7.3 per 
1000 person-years in the comparison group (for a total of 7.8 per 1000 person-years). The log rank tests indicated 
that patients with RVO developed AMI significantly more frequently than the comparison group overall (Fig. 1A; 
p < 0.001), in the age group < 65 years (Fig. 1B; p < 0.001), and in males aged < 65 years (Fig. 1C; p < 0.001). 
Figure 1B indicated that RVO was an important predictor for AMI in adults younger than 65 years of age because 
the difference in the AMI-free survival rate between the RVO group and the comparison group in adults older 
Variables
Comparison group 
(column %)
RVO group 
(column %) P value
Acute myocardial infarction < 0.001
 No event 7,923 (94.7) 1549 (92.4)
 Event 444 (5.3) 128 (7.6)
Hypertension < 0.001
 No 2,796 (33.4) 282 (16.8)
 Yes 5,571 (66.6) 1395 (83.2)
Diabetes mellitus < 0.001
 No 3,984 (47.6) 584 (34.8)
 Yes 4,383 (52.4) 1093 (65.2)
Chronic renal failure < 0.001
 No 8,113 (97.0) 1578 (94.1)
 Yes 254 (3.0) 99 (5.9)
Dyslipidaemia < 0.001
 No 3,205 (38.3) 443 (26.4)
 Yes 5,162 (61.7) 1234 (73.6)
Stroke 0.020
 No 8,219 (98.2) 1633 (97.4)
 Yes 148 (1.8) 44 (2.6)
Variables for matching
Year
 2003 1,641 (19.6) 329 (19.6) > 0.999
 2004 1,893 (22.6) 379 (22.6)
 2005 1,581 (18.9) 317 (18.9)
 2006 1,473 (17.6) 295 (17.6)
 2007 1,779 (21.3) 357 (21.3)
Age group (year) > 0.999
 < 50 1,205 (14.4) 241 (14.4)
 50–59 1,963 (23.5) 393 (23.4)
 60–69 3,076 (36.8) 616 (36.7)
 70–79 1,662 (19.9) 334 (19.9)
 ≥ 80 461 (5.5) 93 (5.6)
Sex 0.987
 Male 3,659 (43.7) 733 (43.7)
 Female 4,708 (56.3) 944 (56.3)
Residence > 0.999
 Seoul (metropolitan) 1,774 (21.2) 355 (21.2)
 2nd area 1,507 (18.0) 302 (18.0)
 3rd area 1,839 (22.0) 369 (22.0)
 4th area 3,247 (38.8) 651 (38.8)
Household income > 0.999
 0–30% 1,896 (22.7) 380 (22.7)
 30–70% 2,748 (32.8) 551 (32.9)
 70–100% 3,723 (44.5) 746 (44.5)
Table 1.  Characteristics of the study population comparison group (n = 8,367) and the retinal vein 
occlusion (RVO) group (n = 1,677). Seoul, a metropolitan area in Korea; the 2nd area included the largest 
province; the 3rd area included the second largest city and two 2nd and 3rd largest provinces; and the 4th area 
included other areas.
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than 65 years was much smaller than that observed in younger adults. Figure 1C indicated that RVO was an 
important predictor for AMI in males aged < 65 years, whereas the AMI-free survival rate was similar between 
females with RVO and females without RVO.
Discussion
In this study, we examined the association between RVO and AMI in 10,044 sociodemographically matched 
subjects extracted from a nationwide 12-year longitudinal cohort database of 1,025,340 Koreans. We found that 
RVO patients exhibited a higher risk for the development of AMI during an up to 11-year follow-up period after 
adjusting for comorbidities and sociodemographic factors.
Despite remarkable progress in medical science, myocardial infarction remains an important health prob-
lem20, and the incidence of AMI has been on the rise in Asia (which is opposite to the trend reported in the 
United States) due to the Westernization of the diet and the aging of the population21–23. The clinical importance 
of cardiovascular disabilities and the possibility of the association between RVO and AMI development or myo-
cardial infarction mortality have spurred several previous studies, but the results have been inconsistent11–17,24–27. 
A relatively small sample size, short follow-up period, and insufficiently representative samples generated from a 
single centre constitute limitations that may have caused the inconsistent results in previous studies. In terms of 
myocardial infarction mortality, a pooled data analysis of two Caucasian population-based cohorts reported that 
Variables
Univariable Cox Multivariable Cox
HR (95% CI) p–value HR (95% CI) p–value
Group
 Comparison group 1(ref) 1(ref)
 RVO group 1.45 1.19 – 1.76 < 0.001 1.25 1.02 – 1.52 0.029
Hypertension
 No 1(ref) 1(ref)
 Yes 3.71 2.84 – 4.85 < 0.001 2.64 1.98 – 3.50 < 0.001
Diabetes mellitus
 No 1(ref) 1(ref)
 Yes 1.50 1.26 – 1.78 < 0.001 1.01 0.83 – 1.21 0.957
Chronic renal failure
 No 1(ref) 1(ref)
 Yes 2.62 1.94 – 3.53 < 0.001 1.83 1.35 – 2.49 < 0.001
Dyslipidaemia
 No 1(ref) 1(ref)
 Yes 1.44 1.19 – 1.74 < 0.001 1.09 0.89 – 1.34 0.386
Stroke
 No 1(ref) 1(ref)
 Yes 2.13 1.38 – 3.29 0.001 1.59 1.02 – 2.46 0.039
Age group (year)
 < 50 1(ref) 1(ref)
 50–59 1.91 1.27 – 2.89 0.002 1.61 1.06 – 2.43 0.026
 60–69 3.43 2.35 – 5.02 < 0.001 2.61 1.77 – 3.85 < 0.001
 70–79 4.41 2.98 – 6.52 < 0.001 3.19 2.13 – 4.78 < 0.001
 ≥ 80 6.44 4.04 – 10.25 < 0.001 4.67 2.91 – 7.50 < 0.001
Sex
 Male 1(ref) 1(ref)
 Female 0.81 0.69 – 0.95 0.012 0.73 0.62 – 0.86 < 0.001
Residence
 Seoul (metropolitan) 1(ref) 1(ref)
 2nd area 1.02 0.78 – 1.33 0.879 1.08 0.83 – 1.41 0.564
 3rd area 1.05 0.82 – 1.35 0.680 1.14 0.89 – 1.47 0.289
 4th area 1.03 0.83 – 1.29 0.773 1.08 0.87 – 1.35 0.488
Household income
 0–30% 1(ref) 1(ref)
 30–70% 0.97 0.78 – 1.22 0.802 1.03 0.82 – 1.29 0.811
 70–100% 1.00 0.81 – 1.23 0.973 0.93 0.75 – 1.15 0.502
Table 2.  Univariable and multivariable Cox regression analysis for the overall incidence rate of acute 
myocardial infarction (n = 10,044). CI = confidence interval; HR = hazard ratio; RVO = retinal vein 
occlusion. Seoul, a metropolitan area in Korea; the 2nd area included the largest province; the 3rd area included 
the second largest city, and two 2nd and 3rd largest provinces; and the 4th area included other areas.
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baseline RVO was associated with a higher cardiovascular mortality rate in persons aged < 70 years after adjusting 
for age, gender, body mass index, hypertension, diabetes, smoking, glaucoma, and study site26. However, there 
was no significant difference in the mortality risk between persons of all ages with and without RVO. Another 
study using the Framingham algorithm estimated higher mortality resulting from cardiovascular disease among 
patients with RVO13. In contrast, another study found that mortality was not higher in CRVO patients12. However, 
cardiovascular or overall mortality may not fully explain the association between RVO and AMI, and the mortal-
ity rate is not equal to AMI development when interpreting the results of these studies.
Recently, well–designed population-based studies were conducted to evaluate the association between AMI 
and RVO in several regions. A methodologically similar study using a Taiwanese nationwide population base 
found that RVO patients did not have a significantly higher rate of AMI during a 3-year follow-up period after 
adjusting for confounding factors (adjusted HR = 1.17 for BRVO group and adjusted HR = 2.33 for CRVO group 
compared to the control)14. When the results of that study were compared with those of the current study, sev-
eral differences were noted. In the Taiwan study, the total number of eligible RVO patients over the four year 
period was 591, of which 11 patients suffered AMI (1.86% of the RVO patients). This number was much smaller 
than the 1,677 RVO patients eligible over the five year period and the 128 patients who suffered AMI (7.6% of 
the RVO patients examined) in the current study. According to previous studies based on the national health 
insurance database, the incidence and rates of AMI in Korea (118.4 and 91.8 per 100,000 persons, respectively, in 
2007) were higher than those in Taiwan (62.4 and 55.7 per 100,000 persons, respectively, in 2008)21,22. The small 
number of cases and relatively short study period in Taiwan may have resulted in insufficient power to detect the 
associations.
Another large study comparing 4500 patients with RVO and 13,500 controls based on a health care claims 
database in the US reported that the event rates for AMI were similar in patients with RVO and the controls 
after adjusting for confounding factors (adjusted rate ratio = 1.03, 95% CI 0.75 to 1.42)15. In the subgroup anal-
ysis, males and patients younger than 65 years with RVO had adjusted HRs of 1.6 and 1.9 for AMI, respectively, 
Variables
Age group
Age < 65 years (n = 5,726) Age ≥ 65 years (n = 4,318)
HR (95% CI) p–value HR (95% CI) p–value
Group
 Comparison group 1(ref) 1(ref)
 RVO group 1.47 1.10 – 1.98 0.010 1.05 0.80 – 1.37 0.749
Hypertension
 No 1(ref) 1(ref)
 Yes 3.36 2.30 – 4.90 < 0.001 2.34 1.53 – 3.59 < 0.001
Diabetes mellitus
 No 1(ref) 1(ref)
 Yes 0.97 0.73 – 1.29 0.835 1.06 0.83 – 1.36 0.632
Chronic renal failure
 No 1(ref) 1(ref)
 Yes 2.00 1.20 – 3.32 0.008 1.75 1.20 – 2.57 0.004
Dyslipidaemia
 No 1(ref) 1(ref)
 Yes 0.98 0.72 – 1.34 0.916 1.20 0.92 – 1.56 0.187
Stroke
 No 1(ref) 1(ref)
 Yes 1.77 0.90 – 3.46 0.097 1.45 0.81 – 2.58 0.211
Sex
 Male 1(ref) 1(ref)
 Female 0.68 0.53 – 0.88 0.004 0.78 0.63 – 0.97 0.028
Residence
 Seoul (metropolitan) 1(ref) 1(ref)
 2nd area 0.82 0.52 – 1.29 0.395 1.22 0.87 – 1.69 0.246
 3rd area 1.38 0.94 – 2.02 0.102 0.98 0.70 – 1.36 0.884
 4th area 1.25 0.88 – 1.77 0.211 0.93 0.69 – 1.24 0.603
Household income
 0–30% 1(ref) 1(ref)
 30–70% 1.04 0.74 – 1.45 0.829 1.01 0.74 – 1.38 0.949
 70–100% 0.85 0.61 – 1.20 0.360 1.00 0.76 – 1.31 0.973
Table 3.  Multivariable Cox regression analysis for the overall incidence rate of acute myocardial infarction 
according to age group (n = 10,044). CI, confidence interval; HR, hazard ratio; RVO = retinal vein occlusion. 
Seoul, a metropolitan area in Korea; the 2nd area included the largest province; the 3rd area included the second 
largest city, and two 2nd and 3rd largest provinces; and the 4th area included other areas.
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compared with the controls. The present study showed similar results in terms of a stronger association between 
RVO and AMI in younger adults and/or males. RVO was associated with an increased risk of AMI (HR = 1.25, 
95% CI 1.02 to 1.52), and our subgroup analysis showed that RVO patients aged < 65 years and males aged < 65 
years had a significantly higher risk (HR = 1.47, 95% CI 1.10 to 1.98; and HR = 2.00, 95% CI 1.38 to 2.91, respec-
tively) for the development of AMI after adjusting for possible confounding factors. Finally, the present study 
showed a clearer association between RVO and AMI than other studies because our study had a longer duration 
with an up to 11-year follow-up period (median 7.7 years), a large number of RVO patients (70.4% power with a 
sample size of 10,000), and a relatively increasing trend in the AMI incidence in Korea (7.8 occurrence per 1,000 
person-year) that was in contrast to the decreasing trend found in other developed Western countries21–23.
A previous INTERHEART global case-control study from 52 countries showed that traditional risk factors 
were generally stronger in association with AMI development among younger adults compared to older adults 
and that hypertension was more strongly associated with AMI in females than males28. Our results were consist-
ent with the differences in age- and gender-based associations between comorbidities and AMI. In younger adults 
aged < 65 years, hypertension (HR = 3.36) was the most important risk factor for AMI and RVO (HR = 1.47), 
chronic renal failure (HR = 2.00) and stroke (HR = 1.77) increased the risk of AMI. In older adults aged ≥ 65 
years, RVO was no longer a significant predictor for AMI, whereas hypertension (HR = 2.35) and chronic renal 
failure (HR = 1.77) were associated with AMI. Moreover, in younger adults aged < 65 years, RVO was associated 
with the male gender (HR = 2.00) and not the female gender (HR = 0.93, Table 4). Figures 1B,C described the 
importance of age and gender in using RVO as a predictor for AMI. Figure 1C showed that RVO was a particu-
larly important risk factor for AMI in men aged < 65 years in addition to other classic systemic comorbidities. 
The pathophysiology responsible for RVO development may differ according to age. It is generally recognized that 
retinal vein inflammation is a primary cause of RVO in young patients29. In older patients, RVO is more related 
to compression of the retinal vein due to atherosclerotic changes in the neighbouring arterioles in which a retinal 
vein is compressed by an adjacent retinal artery, resulting in thrombus formation and retinal ischemia8,30. These 
age-dependent RVO mechanisms may be associated with differences in the AMI rate in different age groups. RVO 
could be another candidate in the risk profiles for the development of AMI in young males. Although overall 
Variables
Age < 65 years
Male (n = 2,684) Female (n = 3,042)
HR (95% CI) p–value HR (95% CI) p–value
Group
 Comparison group 1(ref) 1(ref)
 RVO group 2.00 1.38 – 2.91 < 0.001 0.92 0.56 – 1.52 0.746
Hypertension
 No 1(ref) 1(ref)
 Yes 3.41 2.03 – 5.72 < 0.001 3.30 1.90 – 5.73 < 0.001
Diabetes mellitus
 No 1(ref) 1(ref)
 Yes 0.99 0.68 – 1.45 0.963 0.92 0.60 – 1.41 0.704
Chronic renal failure
 No 1(ref) 1(ref)
 Yes 1.98 1.04 – 3.75 0.037 1.99 0.86 – 4.60 0.108
Dyslipidaemia
 No 1(ref) 1(ref)
 Yes 1.06 0.70 – 1.60 0.780 0.89 0.55 – 1.44 0.631
Stroke
 No 1(ref) 1(ref)
 Yes 0.88 0.28 – 2.80 0.831 3.61 1.57 – 8.31 0.003
Residence
 Seoul (metropolitan) 1(ref) 1(ref)
 2nd area 0.98 0.53 – 1.82 0.957 0.65 0.33 – 1.28 0.213
 3rd area 1.59 0.91 – 2.76 0.102 1.16 0.68 – 1.99 0.590
 4th area 1.49 0.91 – 2.44 0.110 0.97 0.59 – 1.62 0.919
Household income
 0–30% 1(ref) 1(ref)
 30–70% 0.94 0.60 – 1.48 0.799 1.19 0.73 – 1.95 0.487
 70–100% 0.80 0.51 – 1.28 0.353 0.96 0.58 – 1.61 0.890
Table 4.  Multivariable Cox regression analysis for overall incidence rate of acute myocardial infarction 
according to gender in younger adults aged <65 years (n = 5,726). CI, confidence interval; HR, hazard ratio; 
RVO = retinal vein occlusion. Seoul, a metropolitan area in Korea; the 2nd area included the largest province; 
the 3rd area included the second largest city, and two 2nd and 3rd largest provinces; and the 4th area included 
other areas.
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morbidity and mortality resulting from AMI have decreased, AMI hospitalization rates for young patients have 
not declined over the past decade in the United States31. In Korea, AMI rates in the young have increased, whereas 
the AMI rates in the older population have decreased32. Considering these medical backgrounds, we should pay 
more attention to young patients with RVO as a high risk cardiovascular disease group, especially for the risk of 
an AMI. AMI can occur during the natural course of coronary atherosclerosis, and coronary artery occlusion 
from plaques vulnerable to rupture or erosion is the most common cause of myocardial infarction33,34. In our 
recently published report, we showed that retinal vessel occlusion increased the risk of stroke (HR = 1.48 by RVO; 
HR = 1.78 by retinal artery occlusion)35,36. In this study, RVO increased the risk of AMI. These results may be 
explained by the similarity in the occlusive mechanism of both stroke and AMI. Improved blood pressure control 
might also be helpful in decreasing the risk of AMI in RVO patients. However, this epidemiological study does 
not provide evidence for the pathophysiology behind this finding.
Strengths and limitations of the study. We examined the association between AMI and RVO in a 
nationwide, standardized 12-year longitudinal cohort based on a large sample size of 10,044 patients and controls. 
A relatively large number of RVO patients and a long study period are the main strengths of the present study.
The limitations of this study include: 1) the possibility of misclassification of diagnoses for RVO, AMI, or 
comorbidities, 2) possible underreporting of asymptomatic RVO or AMI patients who did not receive medical 
care, 3) the possibility of delayed visits to the ophthalmologist or cardiologist and thus delayed diagnosis of RVO 
or AMI, respectively, 4) the possibility that chronic RVO patients are not fully excluded, 5) the inability to collect 
other important health-related information, such as alcohol consumption, 6) the possibility that a medical claim 
may have included biased controls compared to general population-based controls who neither received medical 
care nor had a specific diagnosis, 7) the possibility that racial differences may exist in the South Korean popu-
lation and 8) the lack of access to data regarding the types of RVO (central or branch) or classification of AMI 
(non-ST elevation MI, or ST elevation MI).
The most important limitation of this study was that the RVO diagnoses were defined based on KCD codes, 
which might be inaccurate compared with the diagnoses obtained from a medical chart that included imaging 
results and thus might make misdiagnoses possible. The validity of the medical insurance claims data regarding 
RVO in Korea were discussed in our previous RVO study based on the NHIS-NSC 2002–2010 database35. A pre-
vious study revealed that the accuracy for diagnosing AMI using the ICD-10 codes in the Korean medical insur-
ance claims data was 71.4% according to the World Health Organization and 73.1% according to the American 
College of Cardiology/the European Society of Cardiology Committee criteria; moreover, the reliability was fair 
to good37. To verify the NHIS-NSC 2002–2013 data, the prevalence of 20 major diseases for each year was calcu-
lated to compare the trends in the annual changes in prevalence. KNHIS confirmed that the prevalence of each 
disease was similar, thereby validating the quality of the data. Additionally, the NHIS-NSC 2002–2013 primarily 
included medical claims but only partially included other health examination data, including the body mass 
index and behavioural risk factors such as the smoking status. In this respect, these possible confounding factors 
could not be controlled. Only limited information is available in the NHIS-NSC 2002–2013 claims database, such 
as the procedure code or diagnosis code. Unfortunately, it was impossible to distinguish between branch and 
central RVO, although the two conditions were known to have different risk factors38. Our explanatory analyses 
based on RVO patients who received photocoagulation laser therapy (RVO patients with laser) and who had not 
ever received photocoagulation laser therapy (RVO patients without laser) showed that the effect size (~HR) was 
greater in the RVO patients with laser therapy than in the RVO patients without laser therapy compared to the 
comparison group as a reference group (unadjusted HR = 1.60 for RVO patients with laser therapy and 1.37 for 
RVO patients without laser therapy). Therefore, further clinical studies are needed, including a stratified analysis 
of RVO types.
Figure 1. Acute myocardial infarction (AMI)–free survival rate for the retinal vein occlusion (RVO) group 
and the comparison group (Comp.) over the 11-year follow-up period. The overall AMI-free rate (A) AMI-
free rate by age group (< 65 years and ≥ 65 years) (B) and AMI-free rate by gender in subjects aged < 65 years 
(C) are shown.
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Conclusions
RVO was associated with AMI development after adjusting for potential confounding conditions. The physician 
should keep in mind that RVO is an important predictor for AMI, especially in adult males aged < 65 years. 
Ophthalmologists should be watchful for patients with RVO to control for known risk factors, such as hyperten-
sion and diabetes mellitus, and have the patient checked for these disorders if he or she is not already under the 
care of a primary care physician.
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